Skip to main content

Table 2 Disease Characteristics (N = 102)

From: Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Variable N (%)
Stage at Diagnosis  
   Stage I 12 (11.8%)
   Stage II 33 ( 32.4%)
   Stage III 20 ( 19.6%)
   Stage IV 26 (25.5%)
   Unknown 11 (10.8%)
ER Positive 76 (74.5%)
PR Positive 55 (53.9%)
ECOG PS  
   < 2 34 (33.3%)
   = 2 6 ( 5.9%)
   > 2 3 (3.0%)
   Unknown 59 ( 57.8%)
# Months from initial dx to metastasis (Mean, SD) 37.9 (42.3)
# Months from metastasis to first progression (Mean, SD) a 13.9 (14.8)
Had second disease progression 78 (76.5%)
# Months from 1st to 2nd progression (Mean, SD) 6.6 (5.4)
Deceased Per Medical Record 45 (44.1%)
Metastatic Sites At initial Metastatic Diagnosis At First progression
   Bone 61 (59.8%) 67 (65.7%)
   Brain 0 (0.0%) 2 (2.0%)
   Liver 27 (26.5%) 34 (33.3%)
   Lung 29 (28.4%) 36 (35.3%)
   Peritoneum 6 (5.9%) 6 (5.9%)
   Other 35 (34.3%) 44 (43.1%)
Comorbidities Present (N,%)  
   Hypertension 49 (48%)
   CHF 2 (2.0%)
   History of MI or Stroke 4 (3.9%)
   Other CVD 26 (25.5%)
   Diabetes 18 (17.6%)
  1. aMedian time from metastases to disease progression = 8.8 months